THX Pharma Email Format

Biotechnology ResearchAuvergne-Rhône-Alpes, France11-50 Employees

THX Pharma, the trade name of Theranexus, is a biotechnology company based in Lyon, Auvergne-Rhône-Alpes, focused on therapies for rare neurological diseases. Its lead candidate TX01 targets Niemann-Pick type C disease and Gaucher disease and is planned for commercialization in Europe with Exeltis and in the United States, Canada, and Australia. A second program, Batten-1, targets juvenile Batten disease and could become the first approved therapy for that condition, while the company maintains a platform based on antisense oligonucleotides developed in collaboration with research laboratories to address rare neurological disorders. The firm operates in the biotech sector with a strategy that includes partnerships and licensing to bring treatments to regional markets. In early 2026, Theranexus announced an asset sale transferring Batten-1 worldwide and TX01 rights in the United States and Canada to Biocodex, and the company is listed on Euronext Growth Paris.

Get verified THX Pharma emails free

Company overview Employee directory